Wellinks, a provider of telehealth-enabled remote patient monitoring solutions, has announced the first close of its $10M Series B Funding round from UMass Memorial Health.
Wellinks offers an FDA-cleared Spire Remote Patient Monitoring (RPM) System that helps identify early physiologic changes associated with clinical deterioration, supporting earlier intervention and proactive management of chronic respiratory disease beyond traditional care settings.
“This investment represents validation of the solution we’ve built and the outcomes it delivers,” said Jennifer Barretta, Chief Operating Officer and Interim CEO of Wellinks. “Our approach aims to close care gaps for patients, including those at risk for poor adherence, leading to lower healthcare utilization and a reduced cost of care.”
With fresh Series B funds, Wellinks plans to:
- Expand its commercial footprint and extend cardiopulmonary care to broader and more diverse patient populations, including rural and underserved communities.
- Advance its predictive capabilities by leveraging a growing body of real-world clinical data to strengthen decision support and enhance the Wellinks care solution.
- Expand into additional cardiopulmonary conditions, including congestive heart failure (CHF), by applying its technology and care model across a broader range of high-risk patient populations.